Modulation of cell nucleotide levels of isolated kidney tubules.
The mechanisms responsible for the large increases of intracellular ATP levels seen after isolated rabbit proximal tubules are treated with exogenous adenine nucleotides were studied. Exogenous ATP was rapidly degraded via adenosine as far as hypoxanthine. Degradation of AMP to adenosine was substantially inhibited by beta-glycerol phosphate. In studies of the ability of individual exogenous purines to increase intracellular ATP levels, single large doses of adenosine were less effective than equimolar doses of exogenous ATP but were substantially more effective than exogenous inosine or hypoxanthine. Exogenous guanine derived compounds increased only cell GTP. Incremental delivery of smaller doses of adenosine to maintain medium levels greater than 5 microM or inhibition of adenosine deaminase with erythro-9-[3-(2-hydroxynonyl)]adenine or 2'-deoxycoformicin enhanced the nucleoside's effectiveness. However, the initial increase of cell ATP was still greater after treatment with exogenous ATP than after adenosine and, in the presence of adenosine deaminase inhibition, larger increases of cell ATP were produced by 50 microM adenosine than by 250 microM adenosine. These observations are most consistent with substrate inhibition of adenosine kinase by adenosine. Furthermore, the adenosine kinase inhibitor, 5-iodotubercidin, prevented the increases of cell ATP resulting from exogenous adenosine or exogenous ATP. These studies demonstrate how the differential uptake and utilization characteristics of nucleosides and bases can fully account for the increases of intracellular nucleotides produced in isolated tubules by exogenous purines.
Weinberg
J M
JM
Department of Internal Medicine, Veterans Administration Medical Center, Ann Arbor, Michigan.
Davis
J A
JA
Lawton
A
A
Abarzua
M
M
D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology; D058892:Adenosine Deaminase Inhibitors; D000248:Adenosine Kinase / Q000037:antagonists & inhibitors; D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D001696:Biomechanical Phenomena; D005110:Extracellular Space / Q000378:metabolism; D005260:Female; D005994:Glycerophosphates / Q000494:pharmacology; D066298:In Vitro Techniques; D007684:Kidney Tubules / Q000166:cytology / Q000201:enzymology / Q000378:metabolism*; D009705:Nucleosides / Q000037:antagonists & inhibitors / Q000378:metabolism; D009711:Nucleotides / Q000378:metabolism*; D011687:Purines / Q000494:pharmacology; D011817:Rabbits
D058892:Adenosine Deaminase Inhibitors; D005994:Glycerophosphates; D009705:Nucleosides; D009711:Nucleotides; D011687:Purines; C010192:9-(2-hydroxy-3-nonyl)adenine; D000255:Adenosine Triphosphate; D000248:Adenosine Kinase; D000225:Adenine; C031463:beta-glycerophosphoric acid